KA
HAE icon

Keene & Associates’s Haemonetics HAE Stock Holding History

Keene & Associates’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$851K Buy
10,904
+730
+7% +$58.6K 0.68% 36
2024
Q3 		$818K Buy
10,174
+298
+3% +$24.1K 0.62% 37
2024
Q2 		$817K Sell
9,876
-123
-1% -$10.8K 0.67% 35
2024
Q1 		$853K Buy
9,999
+1,219
+14% +$95.7K 0.64% 37
2023
Q4 		$751K Buy
8,780
+268
+3% +$23.2K 0.62% 38
2023
Q3 		$763K Buy
8,512
+250
+3% +$22.3K 0.61% 38
2023
Q2 		$703K Sell
8,262
-594
-7% -$50.2K 0.55% 35
2023
Q1 		$733K Buy
8,856
+72
+0.8% +$5.83K 0.57% 35
2022
Q4 		$691K Sell
8,784
-1,390
-14% -$112K 0.62% 34
2022
Q3 		$753K Sell
10,174
-1,899
-16% -$136K 0.69% 34
2022
Q2 		$787K Sell
12,073
-1,461
-11% -$86.5K 0.74% 32
2022
Q1 		$856K Buy
13,534
+1,814
+15% +$98.6K 0.7% 35
2021
Q4 		$622K Buy
+11,720
New +$714K 0.54% 38

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Keene & Associates's HAE Position: Q4 2024 in Review

Keene & Associates increased its Haemonetics (HAE) stake by 7.2% in Q4 2024, buying an estimated $58.6K and bringing the position to 10,904 shares worth $851K. The position accounts for 0.68% of the portfolio, ranked #36.

Keene & Associates first reported a position in HAE in Q4 2021 and has held it in 13 quarters since. The position peaked at $856K in Q1 2022. 309 funds tracked by Wall St. Rank hold HAE as of Q4 2024.

  • Keene & Associates held 10,904 shares of Haemonetics worth $851K as of Q4 2024.
  • Keene & Associates bought 730 Haemonetics shares in Q4 2024, an estimated $58.6K.
  • Haemonetics made up 0.68% of Keene & Associates's portfolio in Q4 2024, its #36 holding.
  • Keene & Associates first reported a position in Haemonetics in Q4 2021 and has held it in 13 quarters since.
  • Keene & Associates's Haemonetics position peaked at $856K in Q1 2022.
  • 309 funds tracked by Wall St. Rank held Haemonetics as of Q4 2024.

Based on Keene & Associates's 13F filing for Q4 2024, filed 3 Feb 2025.